Key result
Novel epigenetic and oxidative stress targets show promise for reversing cardiac fibrosis to prevent CVD.
Why the study?
Despite available drugs for cardiac fibrosis, heart failure and resistant hypertension prevalence is increasing, driving the search for promising novel targets to reverse cardiac fibrosis and prevent cardiovascular diseases.
What are the promising novel therapeutic targets for reversing cardiac fibrosis to prevent cardiovascular diseases?
What are the promising novel therapeutic targets for reversing cardiac fibrosis to prevent cardiovascular diseases?
This review highlights emerging therapeutic targets, such as epigenetics and specific enzymes, that may help reverse cardiac fibrosis and prevent subsequent cardiovascular diseases.
Should not yet change clinical practice; leaves open validation of these targets in prospective trials.
Cardiovascular diseases are the primary causes of death worldwide. These days its mortality and deadliness is rising dramatically. Cardiac fibrosis, one of the leading causes of heart diseases, is a common pathological process in cardiac disease. It can also cause sudden death even in those without cardiac symptoms. Experimental studies in animals have identified important pathways such as the Renin-Angiotensin-Aldosterone System (RAAS) and the endothelin pathway that contribute to fibrosis formation. Currently different groups of drugs are used for treatment of cardiac fibrosis including antihypertensive, anti-inflammatory and cardioprotective agents. Despite the availability of these agents, the prevalence of heart failure and resistant hypertension is increasing. Therefore the search for novel targets is not a questionable issue. Recently different studies are being conducted for treatment of cardiac fibrosis specifically acting on epigenetics (ex. MicroRNAs), Receptors (ex. Adenosine receptors), Enzymes (ex. Lysl Oxidase like 2) and Oxidative stress (ex. N-Acetylcysteine). Therefore the current review looks for promising novel targets aiming at reversing cardiac fibrosis as a preventive tool for cardiovascular diseases. Keywords: Cardiac fibrosis, cardiovascular disease, Novel targets DOI : 10.7176/JNSR/9-17-03 Publication date :September 30 th 2019
No takes yet. Share an insight, caveat, or question.
Kaleab Gizaw (2019) conducted a review in Cardiac fibrosis. Novel anti-fibrotic targets (epigenetics, receptors, enzymes, oxidative stress) was evaluated. Novel therapeutic targets including epigenetics, specific receptors, enzymes, and oxidative stress pathways show promise in reversing cardiac fibrosis as a preventive tool for cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: